GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: Compound 185 [WO2018115591A1] [1] | MK-5684 | MK5684 | ODM-208 | ODM208
Compound class:
Synthetic organic
Comment: Opevesostat (ODM-208; MK-5684) is a non-steroidal inhibitor of the cytochrome P450 11A1 (CYP11A1) [2] that catalyses the conversion of cholesterol to pregnenolone. This is the first rate-liming step in steroid hormone biosynthesis. Opevesostat was developed for antineoplastic activity against hormone-driven tumour cells, in which the inhibitor blocks steroid hormone biosynthesis and disrupts proliferation. An important caveat of this mechanistic apporach is that during treatment the steroids that are essential for life (glucocorticoids and mineralocorticoids) must be replaced at physiological doses.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Belle DB, Makela M, Passiniemi M, Pietikainen P, Rummarkko P, Tiainen E, Vaismaa M, Wohlfahrt G. (2018)
Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors. Patent number: WO2018115591A1. Assignee: Orion Corporation. Priority date: 21/12/2017. Publication date: 28/06/2018. |
2. Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M, Karlsson S, Rummakko P, Simola O, Wohlfahrt G et al.. (2022)
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis. Mol Cancer Ther, 21 (12): 1765-1776. [PMID:36129801] |
3. (2024)
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. NEJM Evid, 3 (2): EVIDx2300368. [PMID:38349784] |